Document is current
Any future updates will be listed below
-
Authors
Chabert, Clovis
Khochbin, Saadi
Rousseaux, Sophie
Furze, Rebecca
Smithers, Nicholas
Prinjha, Rab https://orcid.org/0000-0002-2666-3326
Schlattner, Uwe
Pison, Christophe
Dubouchaud, Hervé https://orcid.org/0000-0003-1268-6110
- License Information
-
More Information
Article History
Received: 23 May 2017
Accepted: 30 August 2017
First Online: 21 September 2017
Competing Interests
: R.F., N.S. and R.P. are employees and shareholders in GlaxoSmithKline, which is progressing B.E.T. protein inhibitors through clinical development. C.C., S.K., S.R., U.S., C.P. and H.D. do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.
